Clinical trials: Cancer Patients
Advanced Solid Tumor, Melanoma
VSV-02 Compassionate Use in Advanced Solid Tumors
This is a clinical study for patients with advanced solid tumors who have limited or no effective treatment options available. The study aims to evaluate a new investigational drug called VSV-02 Injection, which is developed by…
- Conditions
- Advanced Solid Tumor, Melanoma, Breast Cancer, Lung Cancer
- Trial name
- NCT07260591
- Testing
- VSV-02 Injection
- Where
- China
- Volunteers
- 6 people
- Sponsor
- The First Affiliated Hospital of Xinxiang Medical College
Carcinoma
ARQ 501 in Combination With Docetaxel in Patients With Cancer
The purpose of this study is to determine the safety of ARQ 501 in combination with docetaxel in patients with advanced or metastatic cancer.
- Trial name
- NCT00099190
- Testing
- ARQ 501
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
DS Stage I Plasma Cell Myeloma, DS Stage II Plasma Cell Myeloma
Bortezomib, Melphalan, and Total-Body Irradiation Before Stem Cell Transplant in Treating Patients With Multiple Myeloma
This phase I/II trial studies the side effects and best dose of bortezomib when given together with melphalan, and total-body irradiation before stem cell transplant and to see how well it works in treating patients with multiple…
- Conditions
- DS Stage I Plasma Cell Myeloma, DS Stage II Plasma Cell Myeloma, DS Stage III Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
- Trial name
- NCT01936090
- Testing
- Bortezomib, Total-Body Irradiation, Melphalan
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Mayo Clinic
Cancer: Recurrent and/or Metastatic Solid Tumours
A Phase I Open-Label, Single-Arm, Dose-Escalation Clinical and Pharmacology Study of CCI-001 as Monotherapy and in Combination With Standard Chemotherapy in Patients With Recurrent and/or Metastatic Solid Tumours
CCI-001 is a novel colchicine derivative that is being developed by PharmaMatrix Holdings Ltd. (PharmaMatrix). The drug binds to tubulin, a component of the microtubule polymers which are required for a wide range of cellular…
- Trial name
- NCT04823897
- Testing
- CCI-001
- Where
- Canada
- Volunteers
- 70 people
- Sponsor
- PharmaMatrix Holdings Ltd
Leukemia, Lymphoma
Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Malignancies or Secondary Myelodysplasia Previously Treated With High-Dose Chemotherapy and Autologous Stem Cell Transplant
RATIONALE: Giving chemotherapy, such as busulfan and fludarabine phosphate, before a peripheral blood stem cell transplant helps stop the growth of cancer cells.
- Conditions
- Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT01118013
- Testing
- anti-thymocyte globulin, donor lymphocytes, filgrastim
- Where
- 10 sites in United States
- Volunteers
- 6 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Recurrent High Grade Gliomas
Protocol to Distinguish Tumor Recurrence From Treatment-Related Necrosis in Patients With High Grade Gliomas
Brain imaging tests are routinely used to detect the presence of a brain tumor or to evaluate the response to treatment. Sometimes the images obtained are not specific and the only way to establish a diagnosis is by obtaining a…
- Trial name
- NCT00942760
- Testing
- 3T MRI
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Radiodermatitis
Preventive Effect of Boron-based Gel on Radiation Dermatitis
Preventive Effect of Boron-based Gel on Radiation Dermatitis
- Trial name
- boron_gel (NCT04239560)
- Testing
- Boron-based Gel (Fibore)
- Where
- Iran
- Volunteers
- 257 people
- Sponsor
- Tabriz University of Medical Sciences
Biliary Tract Cancer
Gemcitabine and Cisplatin With or Without CPI-613 as First Line Therapy for Patients With Advanced Unresectable Biliary Tract Cancer (BilT-04)
The purpose of this research study is to determine the safety and efficacy of CPI-613 (devimistat) in the treatment of advanced biliary tract cancer when used in combination with standard of care chemotherapy (gemcitabine plus…
- Trial name
- NCT04203160
- Testing
- CPI 613, Gemcitabine, Cisplatin
- Where
- 10 sites in United States
- Volunteers
- 75 people
- Sponsor
- University of Michigan Rogel Cancer Center
Metastatic Non-Small Lung Cell Cancer, Recurrent Non-Small Lung Cell Cancer
Phase 2 DoceRamPem for Patients With Metastatic or Recurrent NSCLC Who Progressed on Platinum-Doublet and PD-1/PD-L1 Blockade
This phase 2 trial will evaluate the safety and efficacy of combining immunotherapy with a PD-1 checkpoint inhibitor (Pembrolizumab), an anti-VEGF receptor (Ramucirumab), and a taxane chemotherapy (Docetaxel) in treating patients…
- Conditions
- Metastatic Non-Small Lung Cell Cancer, Recurrent Non-Small Lung Cell Cancer, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8
- Trial name
- DoceRamPem (NCT04340882)
- Testing
- Docetaxel, Pembrolizumab, Ramucirumab
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Emory University
Non-Small Cell Lung Carcinoma
Trial of RNActive®-Derived Cancer Vaccine and Local Radiation in in Stage IV Non Small Cell Lung Cancer (NSCLC)
The purpose of this study is to determine whether the new RNActive derived lung cancer vaccine CV9202 in combination with local radiation therapy is safe, tolerable and immunogenic for the consolidation and maintenance treatment…
- Trial name
- NCT01915524
- Testing
- CV9202, local radiation
- Where
- 13 sites in Austria, Germany and 1 more
- Volunteers
- 26 people
- Sponsor
- CureVac
Diffuse Large B-Cell Lymphoma (DLBCL)
Study of Tisagenlecleucel in Chinese Adult Patients With Relapsed or Refractory Diffuse Large B-cell Non-Hodgkin Lymphoma (DLBCL)
This is a multi-center, phase II study to evaluate the efficacy and safety of CTL019 in Chinese adult patients with relapsed or refractory DLBCL.
- Trial name
- NCT04456023
- Testing
- Tisagenlecleucel
- Sponsor
- Novartis Pharmaceuticals
Diffuse Large B-Cell Lymphoma
Orelabrutinib With R-CHOP-like Regimen for Patients With Newly Diagnosed Untreated Non-GCB DLBCL
The purpose of this study is to evaluate the efficacy and safety of orelabrutinib combined with rituximab，followed by orelabrutinib combined with R-CHOP-like regimen for newly diagnosed untreated Non-GCB DLBCL Patients
- Trial name
- NCT05498259
- Testing
- Orelabrutinib, Rituximab, CHOP-like Regimen
- Where
- China
- Volunteers
- 46 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Breast Neoplasms
Development of a Multi-omics Prediction Model for Immunotherapy Response in Triple-Negative Breast Cancer Subtypes
This study aims to collect clinical samples from breast cancer patients who have undergone or are expected to undergo immunotherapy at our institution.
- Trial name
- NCT06833723
- Testing
- Retrospective Data Collection and Analysis
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences
Chronic Myeloid Leukemia
Leukemic Stem Cell Detection for Chronic Myeloid Leukemia Patients With Major Molecular Response
Multi-Center, national, non-drug, prospective cohort study Target patient number is 100 The amount of CD45+/CD34+/CD38-/CD26+ levels of chronic myeloid leukemia (CML) stem cells in CML patients with and without BCR-ABL…
- Trial name
- NCT04104035
- Where
- Turkey (Türkiye)
- Volunteers
- 100 people
- Sponsor
- Ankara University
Ovarian Cancer
Study of Circulating Tumoral DNA in Ovarian Cancer
Circulating tumor DNA detection and quantification in patients with ovarian cancer.
- Trial name
- NCT01350908
- Testing
- Blood sampling
- Where
- France
- Volunteers
- 25 people
- Sponsor
- Institut Curie
Breast Cancer
A Study of LY573636-sodium in Patients With Metastatic Breast Cancer
The primary purpose of this study is to determine the objective response rate (complete and partial response) for patients who receive LY573636-sodium for metastatic breast cancer.
- Trial name
- NCT00992225
- Testing
- LY573636-sodium
- Where
- 5 sites in United States
- Volunteers
- 43 people
- Sponsor
- Eli Lilly and Company
Recurrent Glioblastoma
A Study of the Effectiveness and Safety of Nivolumab Compared to Bevacizumab and of Nivolumab With or Without Ipilimumab in Glioblastoma Patients
The purpose of the study is to compare the efficacy and safety of nivolumab administered alone versus bevacizumab in patients diagnosed with recurrent glioblastoma (a type of brain cancer, also known as GBM), and to evaluate the…
- Trial name
- CheckMate 143 (NCT02017717)
- Testing
- Nivolumab, Bevacizumab, Ipilimumab
- Where
- 112 sites in United States, Australia and 10 more
- Volunteers
- 529 people
- Sponsor
- Bristol-Myers Squibb
Brain Metastases, Adult
Prospective Double Arm Randomized Trial: WBRT Alone and WBRT Plus Silibinin
The occurrence of brain metastases (BMs) is increasing given the availability of a more accurate radiological imaging such as MRI for detecting also small brain lesions and the most effective systemic therapy able to control…
- Trial name
- NCT05793489
- Testing
- Silibinin
- Where
- Italy
- Volunteers
- 44 people
- Sponsor
- Istituto Clinico Humanitas
Cancer of Rectum
Immunotherapy in Patients With Early dMMR Rectal Cancer
The purpose of this investigator-initiated, multicenter phase II trial is to evaluate the efficacy and tolerability of nivolumab and ipilimumab in patients with stage 1-3 MSI/dMMR rectal cancer.
- Trial name
- RESET-R (NCT05732389)
- Testing
- Nivolumab, Ipilimumab
- Where
- 5 sites in Denmark
- Volunteers
- 39 people
- Sponsor
- Odense University Hospital
Multiple Myeloma
A Study of AT9283 in Patients With Relapsed or Refractory Multiple Myeloma
The purpose of this study is to find out whether the new drug AT9283 will slow the growth of multiple myeloma. Side effects of AT9283 will also be closely monitored.
- Trial name
- NCT01145989
- Testing
- AT9283
- Where
- 6 sites in Canada
- Volunteers
- 8 people
- Sponsor
- NCIC Clinical Trials Group